The CompLEEment-1 trial is one of the largest trials in advanced breast cancer. The phase IIIb trial investigated the safety and efficacy of ribociclib plus letrozole in 3,255 patients. The preliminary results of the first 1,000 patients were presented at ASCO 2018; at ESMO 2018, the results from the subgroup of 39 men were presented. We caught up with Dr Claudio Zamagni at the ESMO Congress to learn more about these results. The subgroup results reveal that the combination of ribociclib and letrozole is well tolerated, and tolerability between males and females was not significantly different. We are still waiting for the results from the full CompLEEment-1 population, but these early data show promise in the treatment of advanced breast cancer for both men and women.
1. What was the background and rationale behind the CompLEEment-1 trial? (0:11)
2. What were the key outcomes and findings from the trial? And what were the findings from the subgroup of men, that you are presenting at this year’s ESMO Congress? (1:15)
3. What are the next steps in this area of research over the coming years? (2:45)
4. What will this mean for clinical practice in the future, particularly for male patients? (4:19)
Speaker disclosures: Claudio Zamagni has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and trastuzumab deruxtecan + pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!